Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 9/20 | 0.39 |
| ▸ | THRA | P10827 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | PCNA | P12004 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584373 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BACEPTPN1THRB | |
| SCHEMBL6845200 | 0.93 | PCNA (0.37) | ITGB3ITGA2BTHRBTHRALMNA | |
| SCHEMBL8189234 | 0.91 | THRB (0.44) | ITGB3ITGA2BACEPTPN1THRB | |
| SCHEMBL24894639 | 0.89 | THRA (0.40) | ITGB3ITGA2BPTPN1THRBTHRA | |
| SCHEMBL17612212 | 0.86 | ITGB3 (0.43) | ITGB3ITGA2BACEPTPN1THRB | |
| SCHEMBL13949735 | 0.84 | THRB (0.41) | THRBTHRALMNAMEN1KMT2A | |
| SCHEMBL24894635 | 0.83 | PCNA (0.35) | THRBTHRALMNAMEN1KMT2A | |
| SCHEMBL1526096 | 0.83 | THRB (0.39) | ITGB3ITGA2BACETHRBTHRA | |
| SCHEMBL12584374 | 0.82 | ITGB3 (0.44) | ITGB3ITGA2BACEPTPN1THRB | |
| SCHEMBL16124513 | 0.82 | ITGB3 (0.46) | ITGB3ITGA2BACEPTPN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018014-A1 | NOVEL COMPOUNDS AND FORMULATIONS | PRO-AL MEDICO-TECHNOLOGIES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-9381255-B2 | Formulations comprising T3 nanoparticles | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381255-B2 | Formulations comprising T3 nanoparticles | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130243868-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243868-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8404281-B2 | Formulations | AVANT GARDE THERAPEUTICS & TECHNOLOGIES LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404281-B2 | Formulations | AVANT GARDE THERAPEUTICS & TECHNOLOGIES LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012170017-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110142947-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110142947-A1 | NOVEL FORMULATIONS | AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142947-A1 | NOVEL FORMULATIONS | TNNI3, TNNT2, TNNC1 | ITGB3 322/4885ITGA2B 2220/4885ACE 562/4885 |
| US-20230018014-A1 | NOVEL COMPOUNDS AND FORMULATIONS | TNNI3, TNNT2, TNNC1 | ITGB3 615/4885ITGA2B 2802/4885ACE 2160/4885 |
| US-20130243868-A1 | NOVEL FORMULATIONS | TNNI3, TNNT2, TNNC1 | ITGB3 322/4885ITGA2B 2220/4885ACE 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.